Blog

AUSTIN, TX / ACCESS Newswire / July 29, 2025 / Thermon Group Holdings, Inc. (NYSE:THR) (“Thermon”), a global leader in thermal management, power distribution, and environmental controls, today announced its universal availability of their new Poseidon™ Liquid Load Bank (for US markets) and Pontus™ Liquid Load Bank (for non-US markets). These advanced systems are designed to accurately simulate real-world thermal and electrical demand, providing mission critical component test validation for data centers and other High Performance Computing (HPC) environments.

The new liquid load banks offer a built-for-purpose solution for the rigorous demands of data center commissioning and start up. They serve as essential test validation systems for critical HPC data center infrastructure, like Coolant Distribution Units, Uninterruptible Power Supplies and back-up power generators.

Key features and benefits of the Poseidon and Pontus Load Banks include:

• A built-for-purpose liquid-cooled load bank targeting the data center commissioning and start-up market, including Integrated Systems Testing.

• Industry-leading performance, sizing, and weight, contributing to the lower total cost of ownership.

• Engineered for data center testing applications – with integrated modern controls and monitoring in a standardized package for quick delivery.

• Simple, easy controls and a comprehensive audible alarm system to indicate high temperature, low flow, and low water conditions.

• Modular design with the ability to connect over 100 units in series to test the increasing IT loads in the industry.

Custom designed and optimized by process heating/heat transfer experts, but standardized for quicker lead times and more value, the Poseidon and Pontus Load Banks boast a robust capacity rating up to 600kW within a compact design. Built for rapid deployment, these lightweight systems feature a mobile, space-saving design, allowing for quick and efficient testing in different locations within modular, mobile HPC and other data center environments.

Poseidon and Pontus load banks provide real-time oversight of the dynamic thermal performance and electrical demands crucial for a modern data center in the rapidly expanding age of artificial intelligence (AI).

“The launch of the Poseidon and Pontus Liquid Load Banks marks a significant milestone for Thermon – greatly expanding our opportunity within the rapidly growing data center market.” said Bruce Thames, President & CEO of Thermon. “As data centers evolve to meet the intense demands of AI and HPC, the need for precise, reliable, and efficient validation tools is paramount. Our new liquid load banks deliver unparalleled performance, mobility, and ease of use, reinforcing Thermon’s commitment to providing innovative solutions that empower our customers to build and operate the most robust and efficient critical infrastructure.”

The new liquid load banks are available globally and are certified to local requirements along with the following applicable standards: UL, CSA, CE, ASME, ANSI, NEMA, PED and NEC, ensuring compliance and reliability across diverse markets.

For more information on the Poseidon and Pontus load banks, click here.

Through its global network, Thermon provides safe, reliable and mission critical industrial process heating solutions. Thermon specializes in providing complete flow assurance, process heating, temperature maintenance, freeze protection and environmental monitoring solutions. Thermon is headquartered in Austin, Texas. For more information, please visit www.thermon.com.

CONTACT:
Michelle Saab,
Senior Manager, Global Marketing
Phone: +1-512-560-5482

SOURCE: Thermon Group Holdings Inc.

View the original press release on ACCESS Newswire

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end

MIAMI, FLORIDA / ACCESS Newswire / July 29, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ketamir-2, a novel oral NMDA receptor antagonist for the treatment of neuropathic pain.

The IND submission included a comprehensive data package encompassing preclinical pharmacology, safety, and toxicology studies, including a pivotal neurotoxicity study in Sprague-Dawley rats which showed no evidence of brain lesions or adverse CNS effects-a key distinction from traditional ketamine, which has been associated with NMDA-linked neurotoxicity and the formation of Olney lesions in similar preclinical models. These findings were reinforced by multiple validated neuropathic pain models-including chemotherapy-induced, diabetic, and nerve ligation-induced neuropathy-where Ketamir-2 consistently demonstrated potent analgesic effects and superior efficacy to gabapentin and pregabalin, with reversal of pain sensitivity observed in select models. The IND also incorporated the Company’s Phase 1 readiness data and manufacturing documentation.

MIRA is nearing completion of the Single Ascending Dose (SAD) portion of its international Phase 1 trial at Hadassah Medical Center in Jerusalem, with dose escalation progressing smoothly. The Company is now preparing to initiate the Multiple Ascending Dose (MAD) portion of the study, which will assess the safety, tolerability, and pharmacokinetics of repeated dosing over several days. These data will help inform optimal dosing strategies as MIRA moves toward a Phase 2a study, with the goal of initiating its first U.S.-based efficacy trial in Q4 2025.

“This IND approval validates the strength of our preclinical data and the differentiated pharmacology of Ketamir-2,” said Erez Aminov, Chairman and CEO of MIRA. “We are executing and advancing with precision and speed, and we believe Ketamir-2 may represent one of the most promising non-opioid, non-controlled neuropathic pain treatments in development today.”

Building on Strong Preclinical Evidence

Ketamir-2 has consistently demonstrated robust efficacy and safety across a range of preclinical studies:

• In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%

• In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity

• In head-to-head studies using the chronic constriction injury (CCI) model-a widely accepted sciatic nerve ligation model of neuropathic pain-in rats, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin

• No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses

• A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine

• Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models, supporting oral CNS activity. Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine, which has very low bioavailability when taken orally. This advantage, along with its selective receptor targeting and long-acting metabolite Nor-Ketamir-2, supports its potential as an at-home treatment option.

• Demonstrated antidepressant and anxiolytic-like effects in validated behavioral models, with no dissociative or psychotomimetic side effects

Select findings were recently published in Frontiers in Pharmacology, confirming the molecule’s clean pharmacological profile and positioning Ketamir-2 as a differentiated and scalable alternative to existing treatments. Additional preclinical publications are in progress.

Phase 2a Pathway and Strategic Expansion

With IND clearance secured, MIRA plans to initiate a U.S.-based Phase 2a clinical trial in neuropathic pain in Q4 2025. In parallel, the Company is:

• In discussions with a leading U.S. institution to explore a dedicated trial in chemotherapy-induced peripheral neuropathy (CIPN)

• Evaluating a Phase 2a study in diabetic peripheral neuropathy (DPN), a large, underserved indication with rising prevalence

• Advancing formulation development for topical Ketamir-2 for localized pain applications

Neuropathic Pain: A High-Impact Opportunity Across North America

Neuropathic pain is a widespread and growing concern across North America, with prevalence expected to rise due to aging populations and increasing rates of diabetes and cancer-related treatments. Current therapies often provide only modest relief and are frequently associated with side effects such as sedation, dizziness, weight gain, and dependency risk, limiting their long-term use.

In chemotherapy-induced peripheral neuropathy (CIPN), a significant proportion of patients undergoing treatment experience chronic pain symptoms. Meanwhile, access to IV ketamine remains limited to specialized clinics with long wait times, high cost, and logistical burdens. Ketamir-2’s oral, non-dissociative, and non-opioid profile may help overcome these barriers-offering a more accessible and scalable solution for patients in need.

“Ketamir-2 has demonstrated consistent, potent efficacy across preclinical pain models with a clean safety profile and broad therapeutic potential. The IND approval is a testament to our scientific rigor and may pave the way for meaningful clinical translation,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA.

Other Corporate Updates

MIRA also reports that the planned acquisition of SKNY Pharmaceuticals remains on track, with shareholder approval expected in Q3 2025. SKNY-1, the lead asset from SKNY Pharmaceuticals, is a next-generation oral therapy in development for obesity and smoking cessation. In a recent zebrafish model of obesity and craving, SKNY-1 demonstrated up to 30% weight loss, reversal of high-calorie and nicotine-seeking behavior, normalization of appetite hormones, and preservation of muscle mass. Additionally, SKNY-1 reversed anxiety-like behavior in a validated CB1 agonist-induced model, suggesting a favorable neuropsychiatric safety profile. Designed to avoid the psychiatric side effects linked to earlier CB1-targeting drugs and nicotine cessation agents, SKNY-1 could offer a differentiated, well-tolerated alternative to GLP-1s and other interventions. Meanwhile, MIRA-55, the Company’s oral cannabinoid analog, recently showed comparable efficacy to morphine in inflammatory pain models and is under evaluation for further development.

“MIRA is executing at the highest level across all fronts,” added Mr. Aminov. “Ketamir-2’s clinical momentum, the SKNY-1 merger, and advancing MIRA-55 collectively reflect our commitment to delivering innovative, safe, and scalable therapies for patients with limited options. We’re extremely proud of the team’s performance, and we are just getting started.”

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / July 29, 2025 / Europe is reaching a pivotal moment in its industrial transformation. And Systemiq’s latest report, Fossil-Free Plastics: Driving Clean Industrial Leadership in Europe, commissioned by Vioneo, presents a compelling roadmap for reducing carbon emissions from plastic production by accelerating green methanol-to-olefins (MTO) and other fossil-free pathways. It’s a vital piece of the puzzle. But there’s a critical missing layer-one that can’t be filled by chemistry or policy alone.

That missing layer is infrastructure-not of pipes and plants, but of trust and traceability. Because scaling fossil-free plastics isn’t just about making new materials or announcing new targets-it’s about proving what something is, where it came from, and where it ends up. That’s no small feat. But it’s exactly what SMX Ltd. (NASDAQ:SMX) enables. In fact, it does all of that-and more.

The Systemiq report rightly emphasizes accelerating MTO as a viable, cost-competitive drop-in solution for polyethylene and polypropylene. It also identifies four essential drivers to achieve market readiness: early adopter customers, alignment with EU frameworks, harmonized carbon accounting, and smart public funding.

SMX Can Be the Digital Backbone of Circularity

What the report doesn’t mention-but urgently should-is that none of those initiatives can succeed without a verifiable way to track, audit, and certify materials from origin to shelf to end of life. That’s where SMX changes the game. It’s not just a breakthrough-it’s the enabling technology that ties it all together.

And the best part? SMX technology isn’t speculative. It’s operational right now for any company serious about turning circular economy goals into real, measurable action. In this space, SMX may be the only fully scalable platform that connects intention with accountability at the molecular level.

By permanently marking materials, including green methanol-based plastics, SMX enables seamless, end-to-end tracking across the entire supply chain. From production to post-consumer recovery, every link is traceable, transparent, and verifiable.

Imagine a polymer produced from forestry waste, converted through MTO, and encoded with a forensic signature at its origin. That material can then be audited in real time by brand owners, regulators, and recyclers at any stage of its lifecycle. It’s not just about compliance. It’s about building confidence.

And unlike outdated chain-of-custody systems, SMX provides tamper-proof verification. No guesswork. No greenwashing. Just proof.

Meeting the Market Where It’s Headed

Systemiq’s analysis makes one thing clear: even if Europe hits every recycling, reuse, and reduction target, the continent will still need around 28 million tonnes of virgin plastics annually by 2050. The solution isn’t to cut demand-it’s to decouple virgin production from fossil fuels. This means leveraging biomass, captured CO₂, and other renewable resources to meet demand while reducing emissions.

It’s a valid vision. But visions don’t raise capital. Data does.

To unlock the billions in projected investments and demand-side commitments, this transition needs more than ambition. It needs infrastructure investors can trust. SMX delivers that.

Its PCT system lets companies permanently mark, register, and monetize plastic on an open platform-turning environmental claims into certified, tradable assets. Think of it as carbon credits 2.0, only grounded in physical reality. This is especially timely as EU frameworks like the Digital Product Passport (DPP) and Extended Producer Responsibility (EPR) begin requiring exactly this level of verifiable visibility.

Building Trust in a Low-Trust Transition

Let’s not forget: Europe’s shift to fossil-free plastics is as much a credibility challenge as a technical one. Green methanol producers, polymer converters, and brand owners won’t just need to say their materials are sustainable-they’ll need to prove it.

SMX gives them that power. With real-time, tamper-proof traceability, every player in the value chain can operate with confidence. That’s how early-stage investments get de-risked. That’s how high-spec offtake agreements in food packaging and healthcare get signed. And that’s how entire markets get built, not just imagined.

Policy Can’t Carry the Load Alone

Systemiq’s recommendations for demand-side targets, harmonized metrics, and regulatory clarity are spot on. But they’re not enough. Without standardized, verifiable systems to track compliance, even the best-intentioned regulations become bottlenecks instead of catalysts.

Europe has the ambition. MTO and similar innovations have the chemistry. But only SMX offers the infrastructure to make both scalable, provable, and investable.

If Europe wants to lead in fossil-free plastics, it must also lead in how those materials are verified, measured, and trusted. Traceability isn’t optional-it’s foundational. SMX has already built the infrastructure. It’s proven. It’s available. The time for rhetoric is over. With SMX as an ally, time and words are better spent on implementation.

About SMX (Security Matters) Public Limited Company
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned PCT; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Media Contact For This Release:
info@hawkpointmedia.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use

HAYWARD, CALIFORNIA / ACCESS Newswire / July 29, 2025 / Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog’s acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.

Today, Biolog’s TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology – supporting clinical diagnostics in medical laboratories.

“The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows,” said Robert Wicke, CEO at Biolog. “We’re proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades.”

Biolog’s anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeve™ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive.

“This dual achievement reinforces Biolog’s commitment to advancing global access to high-quality tools for anaerobic microbiology,” said Wicke. “Whether you’re working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs.”

About Biolog

Biolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.com

Contact Information

John Proctor, Ph.D.
CCO
jproctor@biolog.com
(408)306-0414

SOURCE: Biolog, Inc.

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / July 29, 2025 / Highlander Silver Corp. (TSX:HSLV) (“Highlander Silver” or the “Company“) is pleased to report assay results from the first seven holes drilled to test a conceptual open pit target along a ridgeline where the Bonita vein system is exposed 10km to the south of the Ayelen underground deposit at its San Luis gold-silver project in Central Peru.

Highlights are listed below, with corresponding images in Figures 1-2 and detailed results in Tables 1-2.

Highlights

• The Bonita vein system is located 10km to the south and 700m lower in elevation than Ayelen. It is exposed in outcrop over an area of 800m by 200m and remains open in all directions

Mr. Daniel Earle, President and CEO, commented: “It’s encouraging to see consistent broad intersections of high grade gold-silver mineralization in shallow step out drilling, particularly from a starting point of only two historical holes. As we continue reporting results, we’re also working to lay the foundation of social support, regulatory permitting and knowledge won from systematic exploration to scale our operations to build momentum through the second half of the year.”

Figure 1 – Plan View of Bonita Vein System

Figure 2 – Image of core from BOD-004 at 35m grading 17.30 g/t Au and 15.10 g/t Ag

Table 1 – Assay Results

Note: Reported intervals are apparent widths as the full geometry of the mineralized structures has not yet been fully modelled. Assays were not capped, and composite intervals are calculated using a minimum weighted average of 0.5 g/t Au, diluted over a minimum core length that allows for internal dilution. Included high-grade intercepts are reported as any consecutive interval with grades greater than 5 g/t Au.

Table 2 – Collar Locations

Technical Information and Quality Control / Quality Assurance

All drilling was completed with HQ core. The drill core is split in half using a diamond saw. Core is logged by the Company’s geologist on site who outlines the intervals to be sampled. The maximum sample length is 1.5 meters and lengths are adjusted according to lithological and/or mineralogical contacts.

After sawing, one-half of the core is kept on site in core boxes, and the other half is submitted for analysis. Individual sample bags are sealed and placed into larger bags, which are then sealed and marked with the contents.

Samples are transported by Highlander Silver personnel to ALS Peru S.A. (“ALS“) located in Lima, Peru, where they are prepared and analyzed. ALS is independent of the Company.

In ALS, the entire sample is crushed to approximately 80% passing through a 2mm sieve. A 500 g fraction is pulverized. Gold concentration is determined by fire assay of a 30-gram charge with an AA finish (Au-AA23). Silver, lead, copper, and zinc, along with other elements, are analyzed by ICP utilizing a four-acid digestion (ME-ICP61). Over-limit samples for Au (10 g/t Au) follow gravitational finishing Au-GRA21 (30g sample). Over-limit samples for Ag (100 g/t Ag) follow gravitational finishing Ag-GRA21 (30g sample).

The internal QA/QC program includes the submission of field duplicates (1/4 core), pulp and coarse reject duplicates, and the insertion of commercial standards and blanks (coarse and fine). Control samples account for more than 15% of the total samples sent, in addition to the laboratory’s internal quality assurance programs.

The Company is not aware of any drilling, sampling, recovery, or other factors that could materially affect the accuracy or reliability of the data referred to herein.

The scientific and technical information, including the drillhole data, has been verified by Dr. Sergio Gelcich. This verification involves data validation and quality assurance procedures, such as reviewing logging directly in front of the core, analyzing database integrity, conducting quality assurance and quality control (QA/QC) for assays, and cross-checking the original lab certificates.

Qualified Person

The scientific and technical information in this press release has been reviewed and approved by Dr. Sergio Gelcich, P.Geo., Vice President, Exploration, Highlander Silver, who is a “Qualified Person” as defined in National Instrument 43-101 Standards of Disclosure for Mineral Projects.

On behalf of Highlander Silver

“Daniel Earle”
President & CEO, Director

Information contact

Arun Lamba, Vice President Corporate Development
alamba@highlandersilver.com

About Highlander Silver

Highlander Silver is primarily focused on advancing the bonanza grade San Luis gold-silver project that is located adjacent to the past-producing Pierina mine in Central Peru. San Luis hosts Indicated Mineral Resources of 356 koz Au at 24.4 g/t Au and 8.4 Moz Ag at 579 g/t Ag and ranks among the 10 highest grade projects globally in both gold and silver categories.¹ The Company’s significant shareholders include the Augusta Group, which boasts an exceptional track record of value creation totaling over $4.5 billion in exit transactions, and strategic shareholders, the Lundin family and Eric Sprott.

¹S&P Global rankings including the San Luis gold-silver project.

The scientific and technical information contained herein is derived from Highlander Silver’s technical report titled “Technical Report on the San Luis Property” with an effective date of January 15, 2025, prepared by independent qualified person, Martin Mount, MSc MCSM FGS CGeol FIMMM Ceng, and available on SEDAR+ at www.sedarplus.ca.

Forward-looking statements

Certain information contained in this news release constitutes “forward-looking information” under Canadian securities legislation. This includes, but is not limited to, expanding the program to include a second drill rig; and the that Company is laying the foundation of social support, regulatory permitting and knowledge won from systematic exploration to scale operations to scale our operations to build momentum through the second half of the year. Such forward looking information or statements can be identified by the use of words such as “ramp up”, “attempting”, “intends”, “believes”, “plans”, “suggests”, “targets” or “prospects” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “will” be taken, occur, or be achieved. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company and/or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking information. Such factors include, among others, general business, economic, competitive, political and social uncertainties, the actual results of current exploration activities, changes in project parameters as plans continue to be refined, future prices of precious and base metals, accident, labour disputes and other risks of the mining industry, and delays in obtaining governmental or stock exchange approvals or financing. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that could cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein are made as of the date of this news release. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. Accordingly, the reader is cautioned not to place undue reliance on forward-looking information.

SOURCE: Highlander Silver Corp.

View the original press release on ACCESS Newswire

Multiple battery system products launched for airport ground support equipment platforms for a a major USA based OEM supplier

Electrovaya to showcase its new products at the International GSE Expo being held in Las Vegas, NV through September 16-18, 2025

TORONTO, ONTARIO / ACCESS Newswire / July 29, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (NASDAQ:ELVA)(TSX:ELVA), a lithium ion battery technology and manufacturing company, is pleased to announce the launch of multiple battery system products designed specifically for airport ground support equipment (GSE). Developed in collaboration with a major original equipment manufacturer (OEM) supplier, these innovative systems support a broad range of electrified ground support equipment (GSE) applications, including airplane tuggers, baggage tractors, belt loaders, cargo loaders, and more.

The Company also confirmed it will be making its first commercial shipment of these new battery systems to the OEM supplier in August, marking a significant milestone in Electrovaya’s strategic expansion into the aviation sector and GSE electrification market.

“This product launch represents a major step forward in our efforts to provide high-performance, durable, and safe lithium-ion battery solutions for an expanded list of mission-critical applications,” said Dr. Jeremy Dang, VP, Business and Project Development. “Airport GSE is an ideal application for our technology given the power demand, long product life span and safety requirement, and the growing global push for cleaner, quieter, and more efficient operations on the tarmac.”

Electrovaya’s battery systems feature the Company’s proprietary lithium-ion Infinity technology, which provides enhanced safety, the longest cycle life in the industry, and robust performance in both hot and cold weather environments-essential characteristics for airport applications operating year-round across diverse geographies.

Electrovaya’s Infinity battery systems feature multiple proprietary innovations, which leads to the Company’s industry leading performance in safety, cycle life, and provides robust performance in both hot and cold weather environments-essential characteristics for airport applications operating year-round across diverse geographies. The Company’s entry into the GSE sector adds to its growing list of mission critical applications where Electrovaya’s innovative batteries are utilized by technologically savvy customers around the world.

The Company will be showcasing these newly launched GSE battery systems at the upcoming International GSE Expo in Las Vegas, Nevada, from September 16-18, 2025. Electrovaya’s team will be available at Booth #4103, to provide product information, answer questions, and discuss collaborative opportunities.

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries without compromising energy and power. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications.Electrovaya has two operating sites in Canada and a 52-acre site with a 137,000 square foot manufacturing facility in Jamestown New York state for its planned gigafactory. To learn more about how Electrovaya is powering mobility and energy storage, please explore www.electrovaya.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements that relate to, among other things, revenue, purchase orders, the potential for demand and orders from the described customers in FY 2026, order growth and customer demand in FY 2026 onwards, future business opportunities, and the ability to deliver to customer requirements, market size and growth potential. Forward-looking statements can generally, but not always, be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “planned”, “objective”, “estimated” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate are necessarily applied in making forward looking statements and such statements are subject to risks and uncertainties, therefore actual results may differ materially from those expressed or implied in such statements and undue reliance should not be placed on such statements. Material assumptions made in disclosing the forward-looking statements included in this news release include, but are not limited to assumptions that the Company’s customers will deploy its products in accordance with communicated timing and volumes, that the Company’s customers will complete new distribution centers in accordance with communicated expectations, intentions and plans, and stable political climate with respect to exports from Canada to the United. Factors that could cause actual results to differ materially from expectations include but are not limited to customers not placing roughly in accordance with historical ordering patterns and communicated intentions, the fact that the expected additional sales from the described customer are expressions of interest and not yet purchase orders, the uncertain effects of the imposition of a new tariff regime on Canadian exports by the United States, macroeconomic effects on the Company and its business and on the lithium battery industry generally, the Company’s liquidity and cash availability in excess of its operational requirements, and the ability to generate and sustain sales orders. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s Annual Information Form for the year ended September 30, 2024 under “Risk Factors”, in the Company’s base shelf prospectus dated September 17, 2024, and in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Qualitative And Quantitative Disclosures about Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Alpha Capital Anstalt, Brenmiller Energy’s largest shareholder and long-standing investor, reinforces its strong commitment to the Company’s long-term strategy

The Company will receive $1.2 million in an initial closing and an additional $3.8 million subject to certain conditions

Alpha Capital Anstalt has Additional Investment Rights for up to $20 million

DIMONA, ISRAEL / ACCESS Newswire / July 28, 2025 / Brenmiller Energy Ltd. (“Brenmiller”, “Brenmiller Energy” or the “Company”) (Nasdaq:BNRG), a leading global provider of thermal energy storage (“TES”) solutions for industrial and utility customers, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Alpha Capital Anstalt (“Alpha”). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to Alpha, subject to certain conditions, up to an aggregate of $25 million in securities across multiple tranches, consisting of preferred shares, pre-funded warrants, and ordinary warrants.

At the initial closing, expected to take place on or about July 28, 2025, for a subscription amount of $1.2 million the Company will issue (i) pre-funded warrants to purchase 631,579 ordinary shares at an exercise price of $0.00001 per share (the “Pre-Funded Warrants”) and (ii) ordinary warrants to purchase 631,579 ordinary shares at an exercise price of $2.09 per share (the “Ordinary Warrants”). The Pre-Funded Warrants will be exercisable upon issuance and will expire when exercised in full. The Ordinary Warrants will be exercisable upon issuance and expire five years from the initial exercise date. The exercise of the Pre-Funded Warrants and Ordinary Warrants are subject to certain beneficial ownership limitations contained therein.

Subject to receipt of certain shareholder approvals, the Company will issue preferred shares with a stated value of $1,000 per share, or the Preferred Shares, in exchange for an additional $3.8 million investment (the “Equity Closing”). Each Preferred Share is convertible into ordinary shares at a fixed conversion price of $2.288 per share. At the Equity Closing, the Company will also issue accompanying ordinary warrants, with an exercise price of $2.40 per share (the “Additional Ordinary Warrants”), equal to 100% of the shares underlying the Preferred Shares, which will be exercisable upon issuance and will expire five years from the initial exercise date.

The proceeds from the financing will be used for general corporate purposes, working capital, and execution of Brenmiller’s commercial TES projects across Europe, the U.S., and the Middle East.

Under the terms of the Securities Purchase Agreement, subject to certain conditions and as long as any Preferred Shares or Additional Ordinary Warrants are outstanding, Alpha also has the right to purchase additional preferred shares and warrants from the Company up to an additional $20 million (“Subsequent Financing”).

The Securities Purchase Agreement also provides for certain additional fundings by Alpha after the Equity Closing which can come in the form of warrant exercises, Subsequent Financing or other financing arranged by Alpha (the “Additional Funding”), subject to certain conditions, up to $15 million, over a two year period beginning after the Equity Closing. Assuming full exercise of all warrants, the overall financing from Alpha may reach $50 million.

Approval of the Company’s shareholders is required for the Equity Closing under the Company’s constitutive documents and applicable law allowing for, among other things, the issuance of the Preferred Shares, including all the underlying shares, and for the Company to issue in excess of 24.99% of the Company’s ordinary shares outstanding on the Equity Closing (including any existing ordinary shares held by Alpha).

In addition, on July 25, 2025, the Company entered into two separate Registration Rights Agreements with Alpha pertaining to (i) the resale of the ordinary shares issuable upon exercise of the warrants issued at the Pre-Funded Warrants Closing and (ii) the resale of the ordinary shares issuable upon conversion of the Preferred Shares and exercise of the Additional Ordinary Warrants to be issued at the Equity Closing. The Company agreed to file these registration statements with the U.S. Securities and Exchange Commission and maintain their effectiveness within specified timeframes.

The securities are being offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act, and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, once issued, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About bGen™

bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company uses forward-looking statements when it discusses: the Company’s ability to raise up to $20 million in Subsequent Financing; the $3.8 million in Preferred Shares and Additional Warrants to be issued upon receipt of shareholder approval; Alpha Capital Anstalt’s providing additional funding up to $15 million over a two year period after the Equity Closing; Alpha Capital Anstalt’s commitment to the Company’s long-term strategy; the use of proceeds from the equity financings described in this press release; and the overall financing which may reach $50 million assuming full exercise of all warrants, which may never be exercised. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

TUALATIN, OR / ACCESS Newswire / July 28, 2025 / Monster Electrical is proud to announce its designation as a Master Distributor for Bussmann Edison fuses, significantly expanding its stocked inventory to better serve industrial and commercial customers nationwide.

With over 17,000 stocked SKUs and 125,000+ parts on hand, Monster Electrical now offers a full line of Bussmann Edison fuses, including Class CC, J, T, RK5, L, G, ECNR, ECSR, Midget, High Speed, and more. Whether it’s a standard order or an emergency replacement, customers can count on fast fulfillment, reliable delivery, and expert support 24/7/365.

“Our customers know us for ‘need-it-now’ solutions,” said Nick Palmer, President at Monster Electrical. “With this partnership, we’re doubling down on that promise-offering the right products when you need them, and the inventory depth to support your everyday stocking needs.”

Monster Electrical operates four strategically located distribution centers across the U.S. (Oregon, New Jersey, Illinois, and Texas), enabling same-day shipping and local pickup for time-critical orders. This expanded inventory supports a wide range of applications across a broad spectrum of the electrical industry.

To browse the full Bussmann Edison fuse catalog or to place an order, visit:

www.monsterelectrical.com/edisonfuses

Contact:
Monster Electrical
888.444.4333
sales@monsterelectrical.com

About Monster Electrical
Monster Electrical is a trusted B2B distributor serving the electrical industry with a focus on fuses and power distribution solutions. With more than 25 years of industry experience, Monster supports OEMs, MROs, and electrical distributors through a nationwide network of stocking locations and over 17,000 SKUs ready to ship. Known for its 24/7 emergency service model and deep product expertise, Monster Electrical offers the reliability, responsiveness, and inventory scale that today’s electrical professionals demand-whether for urgent replacements or ongoing stock replenishment.

SOURCE: Monster Electrical

View the original press release on ACCESS Newswire